Skip to main content
ABT logo

Abbott Laboratories (ABT) Stock: Price, Forecast & Analyst Target

Abbott Laboratories (ABT) — MoonshotScore 71/100 (Strong band), calculated Nov 22, 2026. Price $103.00 (-0.84%), as of the Nov 20, 2026 trading session; market cap $178B. Expected results Jan 28, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 41.41× (market value Nov 22, 2026; cash Sep 30, 2026) · expected results Jan 28, 2027

$103.00 −$0.87 (-0.84%) Market Cap $178B

Abbott Laboratories · ABT · NYSE · Healthcare · Medical - Devices

Research dated 2026-09-12: Abbott Laboratories sells medical devices, diagnostic systems and tests, nutritional formulas, and established medicines; its results therefore reflect several distinct healthcare demand engines rather than a pure device cycle. The case now hinges on whether rising sales can again produce rising operating earnings while expenses absorb more gross profit and the cash balance moves lower.

Price as of Nov 20, 2026

Key Statistics

71 of 100

MoonshotScore v2 · Abbott Laboratories (ABT)

Strong
Business Quality Elite (81)
Financial Safety Okay (42)
Valuation Full (49)
Growth Durability Growing (63)
Momentum Rising (78)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Rising.

  • EPS beat 0 of the last 4 reports
  • expected results Jan 28, 2027
  • Altman Z 3.28 · Piotroski F 6

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ABT (58 recorded, newest six shown)
RecordedScoreBand
72Strong
72Strong
72Strong
69Strong
69Strong
69Strong

The score moved from 69 in the stored Nov 21, 2026 snapshot to 71 in the current publication computed Nov 22, 2026 (+2); the largest pillar moves were Momentum +5 and Valuation -2. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$103.00
Change on the day-0.84%
52-week range$81.97–$129.85
Market capitalisation$178B
Price / earnings (trailing)38.15
Shares traded on the day7.29M
Beta (volatility vs the S&P 500)0.54

Why Abbott Laboratories scores 71

Dr. Mira Sol, the Stock Expert AI TV data character
Business Quality carries the score; Financial Safety is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
71Strong
  • Business Quality81
  • Financial Safety42
  • Valuation49
  • Growth Durability63
  • Momentum78

Share price, last 12 months -13.9%

$127.00 $109.35

What the price assumes

10.9% a year of free-cash-flow growth for ten years is what a $178.00B market value () asks for.

  • Price implies, next ten years10.9%
  • Free cash flow, last 5 years5.3%
  • Revenue, last 5 years5.1%
  • Analysts' revenue path, 2026–20307.1%

The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $6.76B. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 4 of the last 12 reports (2024–2026); the stock still fell the next session after 2 of those beats. Average first-session move: 4.8% either way.

  1. -1.4%Jan ’24
  2. -3.6%Apr ’24
  3. -2.5%Jul ’24
  4. +1.6%Oct ’24
  5. +5.5%Jan ’25
  6. +3.8%Apr ’25
  7. -6.1%Jul ’25
  8. -4.2%Oct ’25
  9. -11.0%Jan ’26
  10. -4.7%Apr ’26
  11. +12.8%Jul ’26
  12. +0.1%Oct ’26
Next-session move EPS beat (4) EPS in line (8)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
In lineIn line+0.1%+0.2%
BeatIn line+12.8%+12.9%
In lineBeat-4.7%-8.9%
In lineMiss-11.0%-12.1%
In lineIn line-4.2%-4.0%
In lineIn line-6.1%-4.6%
BeatIn line+3.8%+2.5%
In lineIn line+5.5%+9.5%
In lineIn line+1.6%+0.8%
BeatIn line-2.5%+1.2%
BeatIn line-3.6%-2.1%
In lineIn line-1.4%-0.7%

Beating the estimate has not been enough: the stock fell after 2 of the last 4 beats. The bar it has to clear is the whisper number, not the published one.

Our track record on this stock

Since the score went from 70 to 69 while the share price moved -11.7% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range

The score has stayed in the Strong band across the stretch we have recorded; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 77% of 43 rate it a buy; the average target ($120.85, captured ) sits +17.3% from the price of $103.00.
  • Last 90 days: 1 upgrade and 1 downgrade among 15 rating actions.
  • Our signals: Strong band; strongest pillar Business Quality (81), weakest Financial Safety (42).

Here we and the crowd agree.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 24, 2025 to Nov 20, 2026: low $84, high $131, latest $103. $131 $84 high $131 Oct 24, 2025 Nov 20, 2026 · $103 $127Oct 24, 2025$126Nov 7, 2025$128Nov 21, 2025$125Dec 5, 2025$125Dec 19, 2025$124Jan 2, 2026$122Jan 16, 2026$109Jan 30, 2026$113Feb 13, 2026$116Feb 27, 2026$108Mar 13, 2026$104Mar 27, 2026$100Apr 10, 2026$91Apr 24, 2026$84May 8, 2026$87May 22, 2026$91Jun 5, 2026$88Jun 18, 2026$95Jul 2, 2026$101Jul 17, 2026$106Jul 31, 2026$111Aug 14, 2026$112Aug 28, 2026$102Sep 11, 2026$101Sep 25, 2026$100Oct 9, 2026$104Oct 23, 2026$110Nov 6, 2026$103Nov 20, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Abbott Laboratories (ABT): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Neutral
Growth Durability Moderate
Momentum Moderate

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Neutral
Debt/Equity Weak
ROE Neutral
Gross Margin Moderate

Read on: Nov 22, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is Abbott Laboratories (ABT), and what does it report?

Short answer · as of

Abbott earns revenue when hospitals and laboratories buy testing platforms, cartridges and automation; when clinicians use cardiovascular, diabetes and neuromodulation products; and when consumers or healthcare channels buy nutritional formulas and established generic medicines.

Medical Devices is the largest reporting segment, but Diagnostics, Nutrition, and Established Pharmaceutical Products make consolidated revenue a measure of several different purchasing patterns.

That mix corrects the obvious reading of Abbott as simply a device maker. A movement in total sales may reflect procedure-related devices, recurring diagnostic consumption, nutrition demand, medicine volumes, or several of these at once, so the segment composition matters as much as the headline.

2 · Latest results

What do the latest results show for Abbott Laboratories (ABT)?

The latest quarter delivered the strongest revenue and gross profit in the reported sequence, yet operating profit fell from the preceding period and net income and diluted earnings weakened. Selling, general and administrative expense rose sharply while research and development spending also increased, absorbing more than the added gross profit; this was a reversal in operating leverage, not a contraction in revenue.

Recent reported results cleared prevailing revenue and earnings estimates, while management framed the near-term outlook through an adjusted earnings range. That distinction matters because the income statement shows weaker reported profit conversion even as the expectation record and management outlook emphasize adjusted earnings.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$13.01B Sep 30, 2026
Latest quarter · R&D
$920.00M Sep 30, 2026
Latest quarter · SG&A
$4.27B Sep 30, 2026
Latest quarter · FMP standardized operating result
$1.36B Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$13.01B$920.00M$4.27B$1.36B
Mar 31, 2026$11.16B$767.00M$3.74B$1.34B
Dec 31, 2025$11.46B$735.00M$3.13B$2.25B
Sep 30, 2025$11.37B$766.00M$3.05B$2.06B
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Jun 2025$11.14B$1.78B$0.00 (diluted)
Sep 2025$11.37B$1.64B$0.94 (diluted)
Q4 FY2025$11.46B$1.78B$1.01 (diluted)
Q1 FY2026$11.16B$1.08B$0.61 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Abbott Laboratories (ABT)?

Short answer

Cash and short-term investments were $4.30B at the Sep 30, 2026 balance-sheet date. Operating cash flow was $1.74B for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Operating cash flow has remained positive throughout the reported quarterly sequence and strengthened in the latest period, giving Abbott internally generated funds despite weaker reported earnings. Liquidity ratios remain workable, and the available distress screen does not signal immediate balance-sheet strain.

Debt nevertheless stands far above cash and investments, leaving Abbott in a net-debt position. Cash and short-term investments have declined across the reported window, including consecutive drops from the recent peak, so sustained expense growth, weaker profit conversion, or a retreat in operating cash flow would reduce financial flexibility.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 38.15 runs well above the Healthcare sector’s ~20.60x, leaving little room for a miss.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$1.74B Sep 30, 2026
Previous quarter · operating cash flow
$1.31B Mar 31, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$1.74B−$513.00M
Mar 31, 2026$1.31B−$399.00M
Dec 31, 2025$3.31B−$689.00M
Sep 30, 2025$2.79B−$496.00M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Abbott Laboratories (ABT)?

Short answer · as of

The next earnings report is expected on Jan 28, 2027.

The next earnings release should be read through revenue quality and conversion: whether sales remain near the recent high, whether operating profit resumes growing with gross profit, and whether selling and administrative costs retreat from their latest step-up. Reported adjusted earnings can then be compared with management’s stated range and the prevailing estimate, while revenue can be tested against the market’s expected expansion.

Cash is the other live check. A rebound in cash and short-term investments alongside continued operating cash generation would ease the tension between healthy cash inflow and the declining balance; another drop would keep attention on uses of cash and the gap between debt and liquidity.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Abbott Laboratories compare with its peers?

Short answer

Abbott Laboratories's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

A focused medical-device company rises and falls mainly with adoption of its devices and the clinical activity that supports their use. Abbott also sells laboratory systems and consumable tests, pediatric and adult nutrition, and established medicines, so consolidated performance combines institutional, clinical, and consumer demand.

Medical Devices remains the largest segment, but Diagnostics and Nutrition are substantial businesses in their own right. This breadth can keep weakness in a particular healthcare category from defining the entire company, while also making group revenue a less precise indicator of device execution than it would be for a specialist.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Edwards Lifesciences Corporation (EW) Same industry, near in market value$101.85 Nov 20, 2026$58.6B94 5-pillar Nov 22, 2026
DexCom, Inc. (DXCM) Same industry, near in market value$79.32 Nov 20, 2026$29.6B93 5-pillar Nov 22, 2026
Penumbra, Inc. (PEN) Same industry, near in market value$319.12 Nov 20, 2026$12.6B93 5-pillar Nov 22, 2026
STERIS plc (STE) Same industry, near in market value$255.76 Nov 20, 2026$24.8B88 5-pillar Nov 22, 2026
Novo Nordisk A/S (NVO) Named competitor$37.82 Nov 20, 2026$167B87 5-pillar Nov 22, 2026
Novartis AG (NVS) Named competitor$150.47 Nov 20, 2026$284B83 5-pillar Nov 22, 2026
Medtronic plc (MDT) Same industry, near in market value$99.94 Nov 20, 2026$128B82 5-pillar Nov 22, 2026
Stryker Corporation (SYK) Same industry, near in market value$310.00 Nov 20, 2026$118B81 5-pillar Nov 22, 2026
Zimmer Biomet Holdings, Inc. (ZBH) Same industry, near in market value$101.10 Nov 20, 2026$19.1B80 5-pillar Nov 22, 2026
Koninklijke Philips N.V. (PHG) Same industry, near in market value$28.61 Nov 20, 2026$28.0B79 5-pillar Nov 22, 2026
Boston Scientific Corporation (BSX) Same industry, near in market value$41.98 Nov 20, 2026$60.9B77 5-pillar Nov 22, 2026
UnitedHealth Group Incorporated (UNH) Named competitor$339.85 Nov 20, 2026$305B76 5-pillar Nov 22, 2026
Abbott Laboratories (ABT) — this page$103.00$178B71

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$112.00 – $130.00
Consensus target
$120.85
Median target
$120.00

Consensus record · Captured .

Measured against a quoted price of $103.00 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 5, 2026

Transactions
25
Identified insiders
11
Purchases
0
Sales
5
Other transactions
20

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ABT in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ABT in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Abbott Laboratories (ABT)?

Read these with our analysis →

What Investors Ask About Abbott Laboratories (ABT) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

Why is Abbott not simply a medical-device company?

Abbott’s largest segment is Medical Devices, but the company also earns substantial revenue from Diagnostics, Nutrition, and Established Pharmaceutical Products. Its headline results therefore combine device adoption with laboratory testing, nutritional demand, and medicine sales.

Why did Abbott’s latest revenue gain not lift operating profit?

Gross profit increased, but selling, general and administrative expense rose sharply and research spending also moved higher. Those expenses more than absorbed the incremental gross profit, leaving operating profit below the preceding period.

What does Abbott’s Established Pharmaceutical Products segment add to the business mix?

The segment supplies generic medicines across a broad set of conditions, adding a pharmaceutical demand stream alongside devices, diagnostics, and nutrition. It makes Abbott’s consolidated sales less dependent on medical procedures alone.

How does Abbott’s falling cash balance fit with positive operating cash flow?

Positive operating cash generation and a declining cash balance can coexist when cash uses elsewhere exceed the period’s inflow. For Abbott, the important observation is that operating cash flow remains positive while cash and short-term investments have moved lower and debt remains materially larger than liquidity.

What is the ABT stock price today?

The last price recorded for Abbott Laboratories (ABT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ABT price target?

The analyst consensus price target for Abbott Laboratories (ABT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 51 figures on this page — 1 from SEC filings and earnings calls, 45 from Financial Modeling Prep (FMP), 2 with no recorded source, 1 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Sector / industry (provider taxonomy); Revenue by segment; Quarterly income statement (USD thousands); Cash and short-term investments over time (USD millions)
  • 1. What is Abbott Laboratories (ABT), and what does it report?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Abbott Laboratories (ABT)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Next earnings report
  • 3. What are the financial strengths and risks for Abbott Laboratories (ABT)?: Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Distress and quality screens; Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value
  • 4. What should you watch next at Abbott Laboratories (ABT)?: Next earnings report; Management outlook — dated call excerpts; Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt
  • 5. How does Abbott Laboratories compare with its peers?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • FAQ: Why is Abbott not simply a medical-device company?: Business description; Sector / industry (provider taxonomy); Revenue by segment
  • FAQ: Why did Abbott’s latest revenue gain not lift operating profit?: Quarterly income statement (USD thousands)
  • FAQ: What does Abbott’s Established Pharmaceutical Products segment add to the business mix?: Business description; Revenue by segment
  • FAQ: How does Abbott’s falling cash balance fit with positive operating cash flow?: Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash, investments and debt; Cash against market value
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold ABT

Funds in our ETF coverage that list ABT among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
VHT ETF2.90%
ProShares - Ultra Health Care (RXL)2.48%
IXJ ETF2.44%